Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

IVA337

Phase 3Small molecule

IInventiva Pharma

1

Indications

4

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

NASH - Nonalcoholic SteatohepatitisActive, not recruiting

NASH - Nonalcoholic SteatohepatitisPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

NASH - Nonalcoholic Steatohepatitis

NCT04849728

Clinical

Trials by Indication[1]

NASH - Nonalcoholic Steatohepatitis2 trials

A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhibitor EmpaGliflozin in patiEnts With Non-alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Completed·IInventiva Pharma·Phase 2·NCT05232071·39 enrolled

A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3

Active, not recruiting·IInventiva Pharma·Phase 3·NCT04849728·1,000 enrolled

Systemic Sclerosis1 trial

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis

Completed·IInventiva Pharma·Phase 2·NCT02503644·145 enrolled

Phase 21 trial

Phase 2b Study in NASH to Assess IVA337

Completed·IInventiva Pharma·Phase 2·NCT03008070·247 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for IVA337. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IVA337 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IVA337. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Inventiva Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInventiva Pharma

Related News